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miR-27b inhibits fibroblast activation via
targeting TGFβ signaling pathway
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Abstract
Background: MicroRNAs are a group of small RNAs that regulate gene expression at the posttranscriptional level.
They regulate almost every aspect of cellular processes. In this study, we investigated whether miR-27b regulates
pulmonary fibroblast activation.
Results: We found that miR-27b was down-regulated in fibrotic lungs and fibroblasts from an experimental mouse
model of pulmonary fibrosis. The overexpression of miR-27b with a lentiviral vector inhibited TGFβ1-stimulated
mRNA expression of collagens (COL1A1, COL3A1, and COL4A1) and alpha-smooth muscle actin, and protein
expression of Col3A1 and alpha-smooth muscle actin in LL29 human pulmonary fibroblasts. miR-27b also reduced
contractile activity of LL29. TGFβ receptor 1 and SMAD2 were identified as the targets of miR-27b by 3’-untranslated
region luciferase reporter and western blotting assays.
Conclusions: Our results suggest that miR-27b is an anti-fibrotic microRNA that inhibits fibroblast activation by
targeting TGFβ receptor 1 and SMAD2. This discovery may provide new targets for therapeutic interventions of
idiopathic pulmonary fibrosis.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, and usually fatal disease. The features of the disease
are characterized by repeated injury and activation of al-
veolar epithelial cells, formation of myofibroblasts and
excessive accumulation of extracellular matrix in the
lung parenchyma [1]. The estimated prevalence of IPF in
the United States is 14 to 27.9 per 100,000 people [2].
However, the etiology and molecular mechanisms of IPF
initiation and progression are largely unclear.
Chronic lung inflammation had been considered pre-
ceding pulmonary fibrosis and played a major role in
lung fibrogenesis. However, some evidence suggested
that inflammation was not an important pathogenic
event of IPF. For example, in the early or late course of
IPF, including diseases similar to mild or moderate alve-
olitis, there was a lack of long-term effective response to
anti-inflammation therapy [3]. Fibroblasts are the main
source of abnormal extracellular matrix production in
IPF. The TGFβ signaling is an important mediator of
pulmonary fibrosis in both animals and humans. TGFβ
modulates the activation of fibroblasts [1]. Alveolar epi-
thelial cells also play an important role in the process of
pathogenesis of IPF. The activated cells secrete soluble
protein factors, including TGFβ, TNFα, endothelin-1 to
exert their effects on fibroblasts [1].
MicroRNAs (miRNAs) are a group of endogenous
non-coding small RNAs. More than 3000 mature miR-
NAs are found from plants to humans. miRNAs are the
key regulators of many biological processes, and they
function by inhibition of translation and degradation of
target mRNAs to control protein expression in physio-
logical and pathophysiological conditions [4]. miRNAs
are involved in almost all aspects of cell physiology, in-
cluding cell proliferation and differentiation, apoptosis,
and diseases [5–8]. Based on computational analysis, the
mRNA targets of miRNAs in most mammals are con-
served due to selective pressure [9].
miR-27b has been reported to play a role in breast,
liver, kidney or other organs. For example, antagomir of
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miR-27b suppressed cell invasion in human breast can-
cer cell line, MDA-MB-231, whereas pre-miR-27b stim-
ulated invasion in ZR75 breast cancer cells [10]. miR-
27b synergized with anticancer drugs in a defined
subgroup of liver and kidney cancer patients [11]. The
overexpression or inhibition of miR-27b in HuH7 cells
significantly decreased or increased the peroxisome
proliferator-activated receptor (PPAR) alpha protein
level [12]. miR-27b targets the 3’-untranslated region (3’-
UTR) of PPARγ and inhibits its mRNA and protein ex-
pression in neuroblastoma cells [13].
Recently, miR-27b was identified as a major miRNA in
modulating TGFβ-induced collagen I expression using a
miRNA inhibitor library [14]. The inhibition of miR-27b
increased COL1A1 expression. However, this study used
lung epithelial cancer cell line A549 cells rather than
pulmonary fibroblasts. During the course of this work,
Cui et al. published a study showing that transfection of
miR-27a-3p mimic into a fetal lung fibroblast cell line
MRC-5 inhibited COL1A2 and alpha-smooth muscle
actin (α-SMA) and this result was confirmed in IPF fi-
broblasts [15]. The use of a miRNA mimic could result
in overwhelmed expression of a miRNA since it by-pass
the cellular regulatory system for the processing of a
miRNA.
In this study, we investigated a role of miR-27b in
fibroblast activation using a human lung fibroblasts and
a lentiviral vector expressing a primary miR-27b, which
is converted into a mature miRNA via the endogenous
processing system after entering cells. We found that
miR-27b inhibited fibroblast activation, and TGFβ recep-
tor 1 (TGFBR1) and SMAD2 are direct targets of miR-
27b. Our results suggest that miR-27b is an anti-fibrotic
miRNA in pulmonary fibroblasts.
Methods
Bleomycin mouse fibrosis model and isolation of primary
cells
The animal procedures were approved by the Institu-
tional Animal Care and Use Committee at the Okla-
homa State University (VM-15–38). Bleomycin or saline
was delivered to the lungs of C57BL/6 male mice (6–8
weeks) via nasal instillation at a dose of 3 U/kg body
weight. On day 14 mice were sacrificed, and lung tissues
were collected. Fibroblasts and alveolar epithelial type II
cells (AEC II) were isolated from the lungs of saline or
bleomycin-treated mice according to the previously de-
scribed protocols [16, 17]. Alveolar epithelial type I cells
(AEC I) were obtained by culturing AEC II in Dulbecco’s
Modified Eagle Medium (DMEM) for 5 days [18].
RNA isolation
Total RNAs were isolated from lung tissues or cells by
using Tri Reagents (Molecular Research Center,
Cincinnati, OH). The RNA concentration and quality were
determined by NanoDrop ND-1000 Spectrophotometer.
Construction of vectors
The primary hsa-miR-27b was PCR-amplified from hu-
man genomic DNA (Promega, Madison, WI) with the
following primers: forward,TTTCTCGAGGGATTACC
ACGCAACCAC and reverse, TTTGAATTCGGCTAG
CATTCCCAGCAGGAGA. The PCR product was
inserted into a modified lentiviral vector pLVX (Clon-
tech, Mountain View, CA) the downstream of its green
fluorescent protein (GFP) at XhoI and EcoRI as de-
scribed [19].
The 3’-UTRs of human TGFβ receptor 1 (TGFBR1)
and SMAD2 were PCR-amplified from human genomic




TAAGGAACG and reverse, GTCGACACAGATGATG
CACACAAATATAT. TGFBR1-UTR or SMAD2-UTR
was inserted into the pmirGlo vector (Promega) the
downstream of firefly luciferase gene at Nhe I and Sac I.
All of the constructs were confirmed by DNA sequencing.
Preparation of lentivirus
To produce lentivirus overexpressing miR-27b, lenti-
miR-27b or its control plasmid was transfected to HEK
293 T cells along with Lenti-X HTX Packaging mix
(Clontech) by using Lipofectamine 2000. After a 48-h
transfection, the media containing viruses were col-
lected. For virus titer determination, HEK 293 T cells
were split into a 12-well plate at a density of 5 × 105cells
per well. Cells were infected with lentiviruses at a series
of dilutions. 48 h post infection, virus titer was deter-
mined by counting GFP-positive cells (10 fields per well)
under a fluorescence microscope.
Infection of fibroblasts with a lentiviral miR-27b
LL29 lung fibroblasts were purchased from American
Type Culture Collection (ATCC, Manassa, VA, CCL-
134) and were maintained in F12K medium supple-
mented with 10% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (P/S). The fibroblasts were seeded on
6-well plates at a density of 2–5 × 105/well. After 24 h,
cells were infected with a lentiviral miR-27b or its con-
trol at a multiplicity of infection (MOI) of 50. 48 h post
infection, cells were stimulated with TGFβ (5 ng/ml).
After another 48 or 72 h, cells were collected for RNA
and protein analyses.
Real-time PCR
Total RNA was reverse-transcribed into cDNA using
Moloney Murine Leukemia Virus reverse transcriptase.
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For miRNA quantitation, total RNA was poly (A)-tailed
using an A-Plus Poly (A) Polymerase Tailing Kit (Epi-
centre, Madison, WI) before reverse transcription. The
following primers were used: COL1A1, Forward: CGAA
GACATCCCACCAATCAC, and reverse: CAGATCAC
GTCATCGCACAAC; COL3A1, Forward: TGGCTA
CTTCTCGCTCTGCTT, and reverse: TTCCAGACA
TCTCTATCCGCATAG; COL4A1 forward: CTCTGG
CTGTGGCAAATGTG, and reverse: CCTCAGGTCC
TTGCATTCCA; α-SMA, forward: GTGTTGCCCC
TGAAGAGCAT, and reverse: CGCCTGGATAGCCA
CATACAT; microRNA-universe reverse primer: GC
GAGCACAGAATTAATACGAC; RNU6 forward primer:
AGAGAAGATTAGCATGGCCCCT; miR-27b forward
primer: TTCACAGTGGCTAAGTTCTGC. Real-time
PCR was performed using SYBR Green master mix on
an ABI 7500 fast system (Applied Biosystems, Foster
City, CA). The thermal temperature were: 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and
65°C for 30 s. The endogenous reference genes were
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
RNU6. The comparative ΔCt method was used to calculate
the relative mRNA and miRNA expression levels.
Luciferase reporter assay
miR-27b or its control plasmid (150 ng) were co-
transfected into HEK 293 T cells using Lipofectamine
2000 with TGFBR1-UTR or SMAD2-UTR plasmid
(5 ng), which contains a Renilla luciferase gene for
normalization. After a 48-h transfection, the cells
were harvested, and luciferase activities were mea-
sured using the Dual Luciferase Reporter Assay Sys-
tem (Promega).
Western blot
Proteins (10–20 μg) were separated on SDS-PAGE and
transferred onto nitrocellulose membranes. After being
incubated with primary antibodies, the membranes were
washed with Tris-buffered saline (pH 7.5) and Tween 20
and incubated with horseradish peroxidase-conjugated
anti-mouse or rabbit secondary antibodies for 1 h. The
target proteins were visualized with Super Signal West
Pico Chemiluminescents Substrate and analyzed with
Amersham 600 Molecular Imager. The following anti-
bodies and dilutions were used: mouse anti-α-SMA
monoclonal antibody (1:1000; Sigma), rabbit anti-β-actin
monoclonal antibody (1:1000; Santa Cruz), rabbit anti-
TGFBR1 polyclonal antibody (1:500; Santa Cruz), rabbit
anti-SMAD2 polyclonal antibody (1:500; Santa Cruz),
rabbit anti-Col3A1 polyclonal antibody (1:500; Santa
Cruz), goat anti-rabbit monoclonal second antibody
(1:2000; Sigma), and goat anti-mouse monoclonal sec-
ond antibody (1:2000; Sigma).
Fibroblast contraction assay
LL29 fibroblasts were seeded in 6-well plates at a density
of 1–2 × 105 cells per well overnight and infected with
miR-27b or its control lentivirus at a MOI of 50 for
48 h. The cells were treated with TGFβ1 (5 ng/ml) for
another 48 h. The cells were trypsinized and mixed with
rat tail collagen I (BD Bioscience, Cat# 354236) to a final
concentration of 1 × 105cells/ml and 1 mg/ml of collagen
1, followed by the addition of 15 μl 0.5 M NaOH to 1 ml
of the cells. The cells were then added to 24-well BSA-
coated plates (500 μl/well). After a 30-min incubation,
medium with or without TGFβ (5 ng/ml) were added
(500 μl/well). Cells were incubated for 48 h and images
were taken. The gel areas were quantified using Image J
software.
Statistics
All experiments were performed with at least three inde-
pendent replicates. For statistical analysis, student t-test
was used for two group comparisons and ANOVA,
followed by Turkey’s test for multiple group compari-
sons. P < 0.05 was considered significance.
Results
miR-27b is down-regulated in the lungs and fibroblasts
from bleomycin-treated mice
We determined miR-27b expression levels in the fibrotic
lungs induced by bleomycin in mice by real-time PCR.
The expression of miR-27b in the lung tissue of
bleomycin-treated mice was decreased significantly com-
pared to that of the control mice (Fig. 1). To examine
which types of the lung cells account for the decrease, we
isolated fibroblasts and alveolar epithelial cells from the
bleomycin-treat mice. The expression level of miR-27b in
fibroblasts was much higher than alveolar epithelial type I
and type II cells (AEC I and AEC II). Bleomycin treatment
reduced miR-27b expression in the fibroblasts (Fig. 1),
suggesting that fibroblasts are the cells responsible for the
reduction of miR-27b in the fibrotic lungs.
miR-27b inhibits pulmonary fibroblast activation
To study whether miR-27b affects fibroblasts’ function, we
overexpressed miR-27b in LL29 human pulmonary fibro-
blasts using a lentiviral vector and determined the effect
of miR-27b on TGFβ1-mediated collagen and α-SMA ex-
pression by real-time PCR and western blotting. The over-
expression of miR-27b in LL29 fibroblasts were confirmed
(Fig. 2a). The mRNA expression of COL1A1, COL3A1,
COL4A1 and α-SMA was increased by TGFβ1 treatment,
and this increase was suppressed by miR-27b overexpres-
sion (Fig. 2b). Moreover, the TGFβ1-induced protein ex-
pression of Col3A1 and α-SMA was also inhibited by
miR-27b overexpression (Fig. 2c, d). These results indicate
that miR-27b represses fibroblast activation.
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miR-27b attenuates the contractile activity in pulmonary
fibroblasts
The contraction process is known to be mediated by spe-
cialized fibroblasts in IPF and TGFβ signaling pathway
regulates this process. Therefore, we investigated whether
miR-27b influences the contractility of pulmonary
fibroblasts. As shown in Fig. 3, miR-27b inhibited the
TGFβ1-induced contractility of LL29 fibroblasts.
miR-27b directly targets TGFBR1 and SMAD2
Because miR-27b inhibits TGFβ1-induced fibroblast acti-
vation, it likely targets the components in the TGFβ
Fig. 1 miR-27b expression in the lung tissues and fibroblasts from bleomycin-treated mice. The lung tissues were collected from saline control (CON)
and bleomycin-treated mice. Fibroblasts and alveolar epithelial type II cells (AEC II) were isolated from the lungs. Alveolar epithelial type I cells (AEC I)
were obtained via trans-differentiation by culturing AEC II for 5 days in vitro. The expression of miR-27b was determined by real-time PCR and normalized
to RNU6 (U6). Data shown are means ± S.E. **P< 0.01. n= 9 for lung tissues; n= 10 for fibroblasts; and n= 3 for AEC I and AEC II. Student t-test
A B
C D
Fig. 2 Effect of miR-27b on fibroblast activation. LL29 fibroblasts were infected with a miR-27b lentivirus or virus control (VC) at a MOI of 50.
a miR-27b expression and b mRNA expression of COL1A1, COL3A1, COL4A1, and α-SMA were determined by real-time PCR. The expression levels
of miR-27b and mRNA were normalized to U6 and GAPDH, respectively. mRNA levels were expressed as fold changes over the control group
without TGFβ1 treatment (CON). c, d The protein level expression of α-SMA and COL3A1 were determined by western blotting and quantitated
using Image J software. The results were normalized to β-actin and expressed as fold changes over control without TGFβ1 treatment (CON). Data
shown are means ± S.E, *P < 0.05, **P < 0.01. n = 3 for a and d, n = 6–10 for b. Student t-test for a and ANOVA, followed by Turkey’s test for b and d
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signaling pathway. Using TargetScan, TGFBR1 and
SMAD2 were identified as the potential targets of miR-
27b (Fig. 4a). Next we constructed 3’-UTR luciferase re-
porter vectors and performed the dual luciferase assay
to validate whether TGFBR1 and SMAD2 are the direct
targets of miR-27b. As shown in Fig. 4b, miR-27b signifi-
cantly inhibited the luciferase activities of TGFBR1-UTR
and SAMD2-UTR reporters. Furthermore, TGFBR1 and
SMAD2 protein expression was inhibited by miR-27b in
LL29 fibroblasts (Fig. 4c, d).
Discussion
miRNAs play important roles in various biological pro-
cesses, such as cell proliferation, differentiation, apop-
tosis, and other functions. miRNAs show different
expression profiles in many diseases including IPF. Ab-
normal expression of miRNAs may contribute to the de-
velopment of many diseases. miRNAs may be potentially
utilized in the treatment of human diseases, such as in-
fectious and metabolic diseases [20, 21]. In the present
study, we demonstrated that miR-27b was down-
regulated in fibrotic lungs and fibroblasts from
bleomycin-induced mouse pulmonary fibrosis model. In
contrast, miR-27a-3p was found to be increased in the
fibroblasts isolated from the lungs of the bleomycin-
treated mice although the same authors found that miR-
27a-3p was decreased in IPF fibroblasts compared to
normal lung fibroblasts [15]. Additionally, TGFβ inhib-
ited miR-27b expression in lung epithelial A549 cells
[14], but increased miR-27a expression in MRC-5 fibro-
blasts [15]. The reasons for these differences remain to
Fig. 3 Effects of miR-27b on contractile activity of lung fibroblasts.
LL29 lung fibroblasts were infected with miR-27b lentivirus or virus
control (VC), and then treated with TGFβ1. The cells were mixed
with collagen I and seeded in 24-well plates for 48 h. Images were
taken and gel areas were quantified using Image J. Collagen gel
contractile activity was calculated as gel surface area divided by well
surface area. The results are expressed as a fold change over VC
without TGFβ1 treatment (CON). Data shown are means ± S.E.,




Fig. 4 TGFBR1 and SMAD2 are the targets of miR-27b. a The binding sites of miR-27b on the 3’-UTRs of TGFBR1 and SMAD2 as predicted by
TargetScan. b 3’-UTR luciferase reporter assay. HEK 293 T cells were transfected with TGFBR1-UTR or SMAD2-UTR luciferase vector together with
the miR-27b expression plasmid or vector control (CON). pmiRGLO is the empty vector without any 3’-UTR sequences. Luciferase activities were
determined 48 h post-transfection. The fold changes were relative to CON for each reporter construct. Data shown are means ± S.E *P < 0.05,
**P < 0.01 n = 4. c, d TGFBR1 and SMAD2 protein levels in miR-27b overexpressing fibroblasts. LL29 fibroblasts were infected with a miR-27b
lentivirus or virus control (VC) at a MOI of 50. After 72 h, the cells were lysed for Western blotting. Protein levels were quantitated by Image J
software and normalized to β-actin. The fold changes were relative to VC. Date were represented as means ± S.E., *P < 0.05, n = 3–4. ANOVA,
followed by Turkey’s test
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be determined, but could be due to the differences in
transcription because miR-27a-3p and miR-27b are lo-
cated in different chromosomes, chromosome19 and
chromosome 9, respectively. However, there is only one
base difference between miR-27a-3p and miR-27b.
The abnormal activation of fibroblasts is one of the
major factors driving fibrotic progression in IPF [22–24].
TGFβ activates fibroblasts and enhances collagen synthe-
sis and extracellular matrix deposition [25–27]. In the
current study, we found that ectopic overexpression of
miR-27b suppressed TGFβ-induced fibroblast activation,
as evidenced by the decreased collagen synthesis, inhib-
ition of α-SMA mRNA and protein expression, and en-
hanced contractile ability. A recent report shows that
miR-27b inhibitor increased TGFβ-induced COL1A1 ex-
pression in lung epithelial A549 cells [14]. The signifi-
cance of this regulation in lung epithelial cells is unclear
since pulmonary fibroblasts are the major cells for extra-
cellular matrix deposition in IPF. Most recently, miR-27a-
3p has been shown to inhibit TGFβ-induced COL1A2 and
α-SMA expression and gel contractility in MRC-5 fibro-
blasts [15]. However, a miR-27b-3p mimic was used for
these studies, which may result in overwhelmed expres-
sion of miR-27a. Further, MRC-5 fibroblasts are derived
from fetal lungs, which may not be the best fibroblast cell
line for studying IPF, which normally occurs in patients
between the ages of 50 and 70 years. Whether miR-27a-3p
and miR-27b have the same functions or are redundant in
pulmonary fibroblasts needs further investigations.
Several miRNAs are involved in the regulation of pul-
monary fibrosis through the TGFβ/SMAD pathway, in-
cluding miR-21, miR-26a and miR-29 [28–30]. We
suspected that miR-27b may act in a similar mechanism
in pulmonary fibrosis. Indeed, TGFBR1 and SMAD2
were identified as potential targets of miR-27b by Tar-
getScan. The dual-luciferase reporter assay confirmed
that miR-27b functioned through a direct binding to its
3-’UTR of TGFBR1 and SMAD2. The endogenous pro-
tein expressions of these targets were reduced in LL29
fibroblasts by miR-27b, which further confirmed that
TGFBR1 and SMAD2 are the targets of miR-27b. Using
similar approaches, Cui et al. found that miR-27a-3p tar-
geted SMAD2/4 in fetal lung MRC-5 fibroblasts and
they also identified α-SMA as an additional target of
miR-27a-3p [15]. In lung epithelial A549 cells, miR-27b
targets gremlin 1 [14]. In neuroblastoma cells, PPARγ is
a target of miR-27b as determined by 3’-UTR luciferase
reporter and endogenous protein assays [13]. In liver
cells, miR-27b regulates PPARα indirectly since overex-
pression of miR-27 reduced the PPARα protein level, but
3’-UTR luciferase reporter assay did not confirm PPARα
as a direct target protein level [12]. It appears that miR-
27a-3p and miR-27b have multiple targets and which
genes are the main targets may depend on cell types.
Conclusions
To sum up, our present studies show that miR-27b plays
an important role in the pulmonary fibroblast activation
by regulating TGFBR1 and SMAD2.
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